Cytospire Therapeutics
United Kingdom, London, United Kingdom
About Cytospire Therapeutics
Cytospire Therapeutics is a London-based biotech developing differentiated multispecific immune cell engager antibodies that activate gamma delta T cells to direct the body's immune system against cancer. Its lead programme, CYT X300, is in IND-enabling preclinical studies and targets EGFR-positive solid tumours including colorectal, head and neck and non-small cell lung cancers. The company's pan-gamma delta T cell engagers are engineered to overcome the efficacy and safety limitations of conventional CD3 T cell engagers.
Latest Funding
Series AAnnounced 2026-05-05
Buying Signals
Where the capital is going, and whether it's already started moving.
Spend Intent
5 signals · where the capital is going
Expand clinical, regulatory and CMC capabilities to support the transition from preclinical to first-in-human studies.
inferred from clinical-stage transition
GMP manufacturing scale-up for CYT X300 ahead of clinical evaluation.
press release
+3 more capital deployment signals · confidence ratings · source articles
Sign up freeIn the news
Selling to Cytospire Therapeutics? You're in the right place.
Knowing they raised is the start. The edge is what's attached to Cytospire Therapeutics.
Spend intent
Where this round will be spent.
Hiring signals
Which departments are growing.
Verified contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Ask AI
What is the unique value proposition of Cytospire Therapeutics, and who are their main competitors?
Sign up free to ask AI about Cytospire Therapeutics
Our AI has read their website, news, and funding history. 25 credits included with every free account.
Sign up free: 25 credits includedAuto-matched to your ICP
Every company, scored against your profile. Automatically.
Industry
High
Size
Mid
Stage
High
Match score blends industry, company size, growth stage, tech stack, and geography. The moment you set your ICP, every company in our database gets scored.
Investors
Abingworth
Lead investor · Series A
Tech Stack
MySQL
PHP
HSTS
Key Highlights
AI InsightsRound was oversubscribed at GBP61M ($83M) with 4BIO Capital leading and a syndicate including Servier Ventures, Sound Bioventures, British Business Bank, Criteria Bio Ventures, Modi Ventures, Medical Incubator Japan and Pathway Bioventures joining alongside existing backers Abingworth and LifeArc Ventures.
AI reads their website, press releases, and funding context to surface what makes them unique - so you tailor your pitch before the first call.
Try it free →Generates a personalized cold email based on their funding round, capital deployment signals, and company context. Ready to send in under 10 seconds.
Try it free →Short, personalized connection request crafted around their recent funding and what your product can help them achieve with it.
Try it free →Maps their competitive landscape with AI - invaluable context before your first call and for positioning your pitch against their alternatives.
Try it free →Extracts capital deployment signals from their funding news - reach out knowing exactly where they're investing and why your product fits.
Try it free →Similar Companies
Discover companies similar to Cytospire Therapeutics
Selling to Cytospire Therapeutics? You're in the right place.
Knowing they raised is the start. Our difference is what comes attached to Cytospire Therapeutics.
Spend Intent
Where this round will be spent.
Hiring Signals
Which departments are growing.
Verified Contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Free weekly newsletter on startup funding.
20 rounds, ranked by amount. Industry and stage breakdowns. A short market note. One email, free, no noise. 2,000+ subscribers.
No spam, ever. Unsubscribe with one click.